Prognostic impact of right ventricular dilatation and echocardiography use criteria in hospitalized COVID-19 patients

doi:10.5662/wjm.v16.i3.117845

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(24)

(22)

(0)

(24)

(237)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Methodol. Sep 20, 2026; 16(3): 117845
Published online Sep 20, 2026. doi: 10.5662/wjm.v16.i3.117845

Table 3 Laboratory, echocardiographic and prognostic parameters in confirmed coronavirus disease 2019 patients (survivors vs non-survivors), n (%)/median (25^th-75^th percentiles)

Parameter	Survivors (n = 90)	Non-survivors (n = 59)	P value
Biomarkers
Lymphocytes (× 10³/μL)	980 (629-1270)	700 (550-910)	0.003
Leukocytes (cells/μL)	9125 (7155-14037)	11805 (9238-16473)	0.001
Neutrophils (cells/μL)	7460 (5426-11965)	9945 (7883-13869)	< 0.001
Hemoglobin (g/dL)	15.0 (11-17)	14.0 (13-15)	0.026
Platelets (×10³/μL)	291 (224-381)	234 (174-331)	0.003
D-dimer (ng/mL)	2,023 (750-3450)	2,761 (879-6900)	0.155
LDH (U/L)	454 (307-610)	506 (379-736)	0.018
C-reactive protein (mg/L)	95 (43-146)	148 (84-196)	0.006
Quantitative echo parameters
E/e′ ratio	10 (10-12)	10 (9-12.8)	0.334
PASP (mmHg)	42.5 (39.5-51.8)	48 (44-51)	0.087
LVEF (%)	60 (55.5-65)	60 (55-65)	0.959
TAPSE (mm)	22 (20-23)	23 (19.8-25)	0.590
Qualitative findings
Prone position during imaging	3 (3.3)	8 (13.6)	0.026
RV dilatation/overload	17 (18.9)	22 (37.3)	0.008
Regional wall-motion abnormality	9 (10.0)	6 (10.)	0.062
Diastolic dysfunction (any)	43 (47.8)	43 (72.9)	0.197

LDH: Lactate dehydrogenase; PASP: Pulmonary artery systolic pressure; TAPSE: Tricuspid annular plane systolic excursion; LVEF: Left ventricular ejection fraction; RV: Right ventricular.

Full Size Table

Citation: Méndez-Toro A, Rojas-Ruiz IT, Silva-DiazGranados LE, Ruano-Cadena A, Paz-Meneses MA, Novoa-Alvarez RA. Prognostic impact of right ventricular dilatation and echocardiography use criteria in hospitalized COVID-19 patients. World J Methodol 2026; 16(3): 117845
URL: https://www.wjgnet.com/2222-0682/full/v16/i3/117845.htm
DOI: https://dx.doi.org/10.5662/wjm.v16.i3.117845

Méndez-Toro A, Rojas-Ruiz IT, Silva-DiazGranados LE, Ruano-Cadena A, Paz-Meneses MA, Novoa-Alvarez RA. Prognostic impact of right ventricular dilatation and echocardiography use criteria in hospitalized COVID-19 patients. World J Methodol 2026; 16(3): 117845 [DOI: 10.5662/wjm.v16.i3.117845]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.